'Molecular wiring of tumour' predicts breast cancer relapse
New research could lead the way to molecular based treatment and follow-up plans Related items fromOnMedica Thousands of women with breast cancer may be spared chemotherapy Benefit of Herceptin in more breast cancer cases MRI in breast cancer fails to cut reoperation rate Mortality higher if using paroxetine and tamoxifen Physical problems after breast cancer limit survival (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 14, 2019 Category: UK Health Source Type: news

Pfizer ’s Herceptin biosimilar wins FDA nod
Roche ’s blockbuster cancer treatment, Herceptin, will now face increasing competition from a new biosimilar. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 11, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Pfizer's biosimilar to Roche's Herceptin
The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin. (Source: Reuters: Health)
Source: Reuters: Health - March 11, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

TILs in Patients on Trastuzumab/Pertuzumab-Based Chemo TILs in Patients on Trastuzumab/Pertuzumab-Based Chemo
Evaluation of baseline TIL percentage may provide prognostic information to patients receiving dual HER2 blockade for breast cancer.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

FDA Approves Trazimera (trastuzumab-qyyp), a Biosimilar to Herceptin
March 11, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab),1 for the treatment of human epidermal growth factor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 11, 2019 Category: Drugs & Pharmacology Source Type: news

T-DM1 Benefits'Striking' in HER2+ Early Breast Cancer T-DM1 Benefits'Striking' in HER2+ Early Breast Cancer
Lidia Schapira provides her perspective on a recent study of trastuzumab emtansine in residual invasive HER2+ breast cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 7, 2019 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Herceptin Hylecta (Trastuzumab and Hyaluronidase-oysk Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Subcutaneous Trastuzumab Formulation for HER2+ Breast Cancer
The US Food and Drug Administration has approved the subcutaneous administration of trastuzumab for patients with HER2-overexpressing breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Adding Checkpoint Inhibition in Trastuzumab-Resistant HER2+ Breast Cancer
An early-phase trial tested the combination of pembrolizumab with trastuzumab in patients with PD-L1 –positive, trastuzumab-resistant, advanced HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 4, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Subcutaneous Herceptin OK'd for Breast Cancer
(MedPage Today) -- Study found 86% of patients preferred it to IV formulation (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - February 28, 2019 Category: OBGYN Source Type: news

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta ™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metast atic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease. (Source: Roche Media News)
Source: Roche Media News - February 28, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta ™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metast atic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - February 28, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers
South San Francisco, CA -- February 28, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2019 Category: Drugs & Pharmacology Source Type: news

NHS prescription charge to rise to £9
20p rise on single prescription fee Related items fromOnMedica NICE rejects breast cancer drug for NHS funding Wales cancer spend at record high JCVI recommends universal HPV vaccination Promise to end new HIV transmissions in England by 2030 NICE recommends Herceptin for gastric cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 21, 2019 Category: UK Health Source Type: news

Can Trastuzumab Therapy Continue After LVEF Decline in HER2+ Breast Cancer?
The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of
Source: CancerNetwork - February 11, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Trastuzumab Biosimilar Proves Mettle in Two Breast Ca Trials (CME/CE)
(MedPage Today) -- Pfizer's biosimilar efficacious and safe for first-line treatment as a branded trastuzumab (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 8, 2019 Category: Hematology Source Type: news

Breast cancer cells shifted into HER2 positive status with bold new strategy
(Scripps Research Institute) One of the most effective breast cancer drugs, Herceptin, is only available to people whose tumors test HER2-positive. That's only one in five breast cancer patients. That could change with a new approach from Scripps Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2019 Category: Cancer & Oncology Source Type: news

MacroGenics stock spikes from positive results of cancer drug trial
Rockville-based MacroGenics Inc. announced positive results Wednesday from late-stage trials of its breast cancer therapy candidate, sending the company ’s stock price soaring nearly 200 percent for the day. The biotech’s margetuximab product — which targets the “HER2” gene, which can feed the growth of cancer cells, specifically in patients with metastatic breast cancer — was found to be safer and better tolerated than Genentech Inc.'s Herceptin, considered a standard treatment today,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 7, 2019 Category: Health Management Authors: Sara Gilgore Source Type: news

MacroGenics stock spikes from positive results of cancer drug trial
Rockville-based MacroGenics Inc. announced positive results Wednesday from late-stage trials of its breast cancer therapy candidate, sending the company ’s stock price soaring nearly 200 percent for the day. The biotech’s margetuximab product — which targets the “HER2” gene, which can feed the growth of cancer cells, specifically in patients with metastatic breast cancer — was found to be safer and better tolerated than Genentech Inc.'s Herceptin, considered a standard treatment today,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 7, 2019 Category: Biotechnology Authors: Sara Gilgore Source Type: news

UCLA ’s Dennis Slamon awarded Sjöberg Prize for pioneering cancer research
Dr. Dennis Slamon, director of the Revlon/UCLA Women ’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with D r. Brian Druker of Oregon Health& Science University.The Sj öberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future ...
Source: UCLA Newsroom: Health Sciences - February 5, 2019 Category: Universities & Medical Training Source Type: news

Roche adapts newer breast cancer drug in face of Herceptin imitations
Swiss drugmaker Roche aims to broaden the use of its Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of its older mainstay Herceptin. (Source: Reuters: Health)
Source: Reuters: Health - February 5, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Roche moves to broaden Kadcyla use in biosimilar defense
Roche aims to broaden use of its Kadcyla breast cancer drug as the Swiss pharmaceuticals giant defends itself against rivals who are crowding in with cheaper biosimilar copies of its older, patent-expired mainstay Herceptin. (Source: Reuters: Health)
Source: Reuters: Health - February 5, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - February 5, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - February 5, 2019 Category: Pharmaceuticals Source Type: news

Pfizer's Trastuzumab Biosimilar Noninferior in Two Breast Ca Trials
(MedPage Today) -- Results similar to branded drug in metastatic, neoadjuvant breast cancer studies (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - February 4, 2019 Category: OBGYN Source Type: news

Ontruzant (Trastuzumab-dttb for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 30, 2019 Category: Drugs & Pharmacology Source Type: news

Samsung Bioepis Biosimilar to Roche's Herceptin Wins FDA Nod Samsung Bioepis Biosimilar to Roche's Herceptin Wins FDA Nod
The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 22, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer
Drug-induced compensatory signaling and subsequent rewiring of the signaling pathways that support cell proliferation and survival promote the development of acquired drug resistance in tumors. Here, we sought to analyze the adaptive kinase response in cancer cells after distinct treatment with agents targeting human epidermal growth factor receptor 2 (HER2), specifically those that induce either only temporary cell cycle arrest or, alternatively, apoptosis in HER2-overexpressing cancers. We compared trastuzumab, ARRY380, the combination thereof, and a biparatopic, HER2-targeted designed ankyrin repeat protein (DARPin; spe...
Source: Signal Transduction Knowledge Environment - January 22, 2019 Category: Science Authors: Schwill, M., Tamaskovic, R., Gajadhar, A. S., Kast, F., White, F. M., Plückthun, A. Tags: STKE Research Resources Source Type: news

Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin. (Source: Reuters: Health)
Source: Reuters: Health - January 18, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Samsung Bioepis-Merck biosimilar to Roche's Herceptin wins FDA nod
The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin. (Source: Reuters: Health)
Source: Reuters: Health - January 18, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin
January 18, 2019 -- FDA today approved Ontruzant (trastuzumab-dttb), a biosimilar to U.S.-licensed Herceptin (trastuzumab). A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an already-FDA... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 18, 2019 Category: Drugs & Pharmacology Source Type: news

Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
DESTINY-Breast04 to evaluate [fam-] trastuzumab deruxtecan (DS-8201) versus investigator's choice in HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemotherapy No anti-HER2 therapies are currently approved for H... Biopharmaceuticals, Oncology Daiichi Sankyo, trastuzumab, breast cancer, HER2 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 14, 2019 Category: Pharmaceuticals Source Type: news

Can Dasatinib Improve Trastuzumab Efficacy in HER2+ Breast Cancer?
Researchers tested whether combining trastuzumab/paclitaxel with dasatinib would have a high response rate in patients with metastatic HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 14, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Liquid Biopsy Tracks Herceptin Resistance in HER2+ Gastric Cancer Liquid Biopsy Tracks Herceptin Resistance in HER2+ Gastric Cancer
Circulating tumor DNA profiling can provide novel insights into gene alterations that underlie trastuzumab resistance in HER2+ metastatic gastric cancer.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 27, 2018 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news

Herzuma (Trastuzumab-pkrb for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 19, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
INCHEON, South Korea& JERUSALEM--(BUSINESS WIRE) December 14, 2018 --Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Herzuma (trastuzumab-pkrb), a HER2/neu... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2018 Category: Drugs & Pharmacology Source Type: news

KATHERINE Results Back New Adjuvant Standard for HER2+ Breast Cancer
Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Charles E. Geyer Jr, MD Source Type: news

Is Cardiac Prophylaxis Effective in Early HER2+ Breast Cancer Patients?
In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity? (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Prophylaxis May Cut Cardiotoxicity Risk in HER+ Breast Cancer
(MedPage Today) -- Clear benefit for anthracycline treatment, not trastuzumab (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 9, 2018 Category: Cardiology Source Type: news

Is Cardiac Prophylaxis Effective in Early HER2+ Breast Cancer Patients?
In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity? (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

New Standard When HER2+ Breast Cancer Isn't Cleared New Standard When HER2+ Breast Cancer Isn't Cleared
' Practice-changing'results support adjuvant trastuzumab emtansine in patients with HER2+ early stage breast cancer who have residual disease following surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

SABCS: T - DM1 Cuts Recurrent Invasive HER2 + Breast CA Risk
Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

Drug Halves Recurrence for Common Breast Cancer
All of the women in the new trial had undergone a standard treatment scenario. First, they received traditional chemotherapy and the drug Herceptin (trastuzumab) -- an antibody that targets HER2-positive cancer cells. Then they had surgery to remove any remaining cancer. (Source: WebMD Health)
Source: WebMD Health - December 5, 2018 Category: Consumer Health News Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

SABCS: T-DM1 Cuts Recurrent Invasive HER2 & #43; Breast CA Risk
WEDNESDAY, Dec. 5, 2018 -- For patients with residual invasive disease after neoadjuvant chemotherapy including a taxane and trastuzumab, substituting trastuzumab emtansine (T-DM1) for adjuvant trastuzumab is associated with a reduced risk for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Breast cancer patients who take heart drug with trastuzumab have less heart damage
(European Society of Cardiology) Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented today at EuroEcho-Imaging 2018. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2018 Category: International Medicine & Public Health Source Type: news

Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
(American Association for Cancer Research) Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50 percent, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2018 Category: Cancer & Oncology Source Type: news

Increase in Liver Cancer Deaths: Clin Onc News Report
(MedPage Today) -- Also, shorter trastuzumab course better? (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 8, 2018 Category: Gastroenterology Source Type: news

Is a Shorter Trastuzumab Duration a Cost-Effective Option in HER2+ Breast Cancer?
Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news